While many top stocks have risen above the fray during periods of market recovery, others haven't followed that upward trend.

U.S. stocks closed rallied on Friday, with the Nasdaq Composite (COMP:IND) securing another back-to-back record, even as ...

Here is why Pfizer's newfound momentum could set the stock up to soar in 2026. Pfizer's generous dividend has become a big ...

Robert F. Kennedy Jr., the health secretary and a longtime vaccine critic, announced in a statement Tuesday that $500 million ...

“Stratus,” originally known as Variant XFG, is the second most prominent strain of COVID in the United States. According to ...

These five large-cap value dividend stocks look poised to provide some second-half gains with steady ultra-high-yield ...

The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...

Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...

The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...